fluorouracil has been researched along with Chromosome Deletion in 10 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Chromosome Deletion: Actual loss of portion of a chromosome.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy." | 5.31 | SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. ( Boulay, JL; Herrmann, R; Laffer, U; Lagrange, M; Lowy, A; Mild, G; Reuter, J; Rochlitz, C; Terracciano, L, 2002) |
| "For many years, 5-fluorouracil was the unique drug approved in the management of colorectal cancer." | 4.85 | [Colorectal cancers: prognostic and predictive factors of response to treatment]. ( Italiano, A; Sablin, MP; Spano, JP, 2009) |
| "A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen)." | 3.73 | Oxaliplatin-related acute myelogenous leukemia. ( Carneiro, BA; Eldibany, M; Kaminer, L; Kaul, K; Locker, GY; Sreekantaiah, C, 2006) |
| " In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy." | 1.31 | SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. ( Boulay, JL; Herrmann, R; Laffer, U; Lagrange, M; Lowy, A; Mild, G; Reuter, J; Rochlitz, C; Terracciano, L, 2002) |
| "Melphalan (MEL) was the only drug used in single-drug chemotherapy." | 1.29 | Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants. ( Friberg, LG; Granberg, S; Islam, MQ; Köpf, I; Levan, A; Levan, G, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Dijk, E | 1 |
| van Werkhoven, E | 1 |
| Asher, R | 1 |
| Mooi, JK | 1 |
| Espinoza, D | 1 |
| van Essen, HF | 1 |
| van Tinteren, H | 1 |
| van Grieken, NCT | 1 |
| Punt, CJA | 1 |
| Tebbutt, NC | 1 |
| Ylstra, B | 1 |
| Labianca, R | 1 |
| Nordlinger, B | 1 |
| Beretta, GD | 1 |
| Mosconi, S | 1 |
| Mandalà, M | 1 |
| Cervantes, A | 1 |
| Arnold, D | 1 |
| Wang, Y | 1 |
| Zhang, C | 1 |
| Gong, T | 1 |
| Zuo, Z | 1 |
| Zhao, F | 1 |
| Fan, X | 1 |
| Yang, C | 1 |
| Song, C | 1 |
| Sablin, MP | 1 |
| Italiano, A | 1 |
| Spano, JP | 1 |
| Boulay, JL | 1 |
| Mild, G | 1 |
| Lowy, A | 1 |
| Reuter, J | 1 |
| Lagrange, M | 1 |
| Terracciano, L | 1 |
| Laffer, U | 1 |
| Herrmann, R | 1 |
| Rochlitz, C | 1 |
| Carneiro, BA | 1 |
| Kaminer, L | 1 |
| Eldibany, M | 1 |
| Sreekantaiah, C | 1 |
| Kaul, K | 1 |
| Locker, GY | 1 |
| Islam, MQ | 1 |
| Köpf, I | 1 |
| Levan, A | 1 |
| Granberg, S | 1 |
| Friberg, LG | 1 |
| Levan, G | 1 |
| Ichikawa, D | 1 |
| Yamaguchi, T | 1 |
| Shirasu, M | 1 |
| Kitamura, K | 1 |
| Inazawa, J | 1 |
| Abe, T | 1 |
| Takahashi, T | 1 |
| Sokova, OI | 1 |
| Volgareva, GM | 1 |
| Kern, L | 1 |
| de Montigny, J | 1 |
| Jund, R | 1 |
| Lacroute, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer Patients as Predictive Factors for Systemic Therapy Outcome[NCT04543019] | 50 participants (Anticipated) | Observational | 2020-12-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Chromosome Deletion
| Article | Year |
|---|---|
[Colorectal cancers: prognostic and predictive factors of response to treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetu | 2009 |
1 trial available for fluorouracil and Chromosome Deletion
| Article | Year |
|---|---|
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chromosome Deletion; Chromosomes; Colon | 2022 |
8 other studies available for fluorouracil and Chromosome Deletion
| Article | Year |
|---|---|
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryoni | 2013 |
An upp-based markerless gene replacement method for genome reduction and metabolic pathway engineering in Pseudomonas mendocina NK-01 and Pseudomonas putida KT2440.
Topics: Carboxylesterase; Chromosome Deletion; Fluorouracil; Genetic Vectors; Genome, Bacterial; Metabolic E | 2015 |
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosome | 2002 |
Oxaliplatin-related acute myelogenous leukemia.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2006 |
Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 1993 |
p53 gene mutation is not directly related to tumoricidal effects of preoperative radiochemohyperthermia therapy for rectal cancers.
Topics: Alleles; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, | 1996 |
[Effect of ftorafur and 5-fluorouracil on the chromosomes of human tumor cell cultures].
Topics: Cells, Cultured; Chromosome Deletion; Chromosomes, Human; Colonic Neoplasms; Fluorouracil; Humans; K | 1979 |
The FUR1 gene of Saccharomyces cerevisiae: cloning, structure and expression of wild-type and mutant alleles.
Topics: Alleles; Amino Acid Sequence; Base Sequence; Chromosome Deletion; Cloning, Molecular; DNA Mutational | 1990 |